News & Events
Published On: 4/14/2020
TARGET-NASH Observational Study Reaches 5,000 Enrolled Patients
Now Largest Real-World Evidence Nonalcoholic Fatty Liver Disease Study in the World
TARGET PharmaSolutions, a real-world clinical data company, today announced that its nonalcoholic fatty liver disease (NAFLD) study, TARGET-NASH, reached 5,000 enrolled patients. TARGET-NASH is now the largest active observational and longitudinal NASH-specific study in the world.
“TARGET-NASH has reached 5,000 enrolled patients in only its fourth year of data collection,” said TARGET PharmaSolutions CEO, Neal Bibeau. “This regulatory-grade data is providing tremendous insight about the burden of the disease and is accelerating our partners’ understanding of these patients and the most effective strategies to bring innovative solutions to treat the disease.”
TARGET-NASH is an observational study of participants diagnosed with nonalcoholic fatty liver (NAFL) and/or NASH. The network of TARGET clinical sites includes both community and academic centers and enrolls adult and pediatric participants across the spectrum of the disease. Once enrolled, three years of retrospective data and five years of prospective data is collected from study participants, including patient-reported outcome measures and biorepository samples.
TARGET-NASH was the first disease community established by TARGET when the company launched in 2015. Since then, TARGET has developed six additional communities including hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), immune-mediated inflammatory skin conditions (DERM), chronic hepatitis B (HBV), and most recently, TARGET-ASTHMA.
To create each real-world community, the TARGET model organizes groups of stakeholders around specific diseases to produce regulatory-grade data and analysis on the disease’s natural history, current treatment paradigms, and patient outcomes. Stakeholders includes key scientific leaders, regulatory agencies, pharmaceutical manufacturers, and patient advocacy groups who are involved in answering critical strategic and planning questions.
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
984.234.0268 ext 205
05/08/2023Real World Evidence Leader Target RWE Shares Expansion and Update on TARGET-GASTRO Longitudinal Study During Digestive Disease Week 2023
03/30/2023Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASH
03/08/2023Ewa Kleczyk, PhD Featured on CIO Views Cover for March – A Memento to Women’s History Month & International Women’s Day
02/28/2023Longest Running Real World Dermatology Registry, TARGET-DERM, Offers Deep Insight into Complex Diseases
01/11/2023Target RWE Launches 35 New Disease State Registries in Complex Indications with High Unmet Medical Needs and Rapidly Evolving Therapies